Phenominer Database Results (15 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 3.95 ml/min 0.7 1.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100465 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 5.45 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100471 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 0.09 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100474 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 24.0 x 10E10 dyne x s/cm5 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pe 100546 2479
WKY afferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 1.04 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 ra 100556 2479
WKY total arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 1.53 x 10E10 dyne x s/cm5 0.12 0.34 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 rt 100566 2479
WKY afferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 18.0 mmHg 0.3 0.85 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 pia 100581 2479
WKY efferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 29.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pie 100586 2479
WKY glomerular transcapillary hydraulic pressure gradient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 31.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 dp 100551 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 0.5 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 re 100561 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 8 4.15 ml/min 0.32 0.91 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100468 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100480 2479
WKY single nephron filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.26 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100526 2479
WKY mean proximal tubular hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 16.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 100541 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100477 2479